Pharmafile Logo
Pharmafocus logo
Advanced Search

plaque psoriasis

Showing 10 posts of 10 posts found.

Bristol Myers Squibb’s deucravacitinib beats Amgen’s Otezla to meet main goal in plaque psoriasis

November 4, 2020
Research and Development BMS, deucravacitinib, plaque psoriasis

Bristol Myers Squibb has unveiled new Phase 3 data showing that its oral, selective tyrosine kinase 2 (TYK2) inhibitor deucravacitinib …

News
janssen_latest_logo_on_sign

FDA expands Stelara indication to cover paediatric plaque psoriasis

July 31, 2020
Medical Communications, Sales and Marketing Janssen, Stelara, pharma, plaque psoriasis

Janssen’s IL-12 and IL-23 inhibitor Stelara (ustekinumab) has had its approved indications expanded by the FDA to include the treatment …

News
janssen_latest_logo_on_sign_closer

Tremfya’s skin clearance benefit lasts up to four years in plaque psoriasis patients, Janssen says

June 15, 2020
Research and Development, Sales and Marketing Janssen, Tremfya, plaque psoriasis

Janssen has revealed new data on its interleukin (IL)-23 inhibitor Tremfya (guselkumab) at the American Academy of Dermatology (AAD) virtual …

News

UCB’s bimekizumab meets primary and secondary endpoints, beating Janssen’s Stelara in chronic plaque psoriasis

October 17, 2019
Research and Development Stelara, UCB Pharma, bimekizumab, pharma, plaque psoriasis

UCB Pharma has announced new data from the first of three Phase 3 studies investigating the efficacy of its IL-17A …

News

New Phase 3 data confirms safety and efficacy of UCB’s Cimzia in plaque and psoriatic arthritis

April 30, 2019
Manufacturing and Production, Research and Development Cimzia, UCB Pharma, pharma, plaque psoriasis, psoriasis

New Phase 3 data has been released by UCB Pharma on the safety of Cimzia (certolizumab pegol) in the treatment …

News

NICE recommends UCB’s Cimzia in severe plaque psoriasis

April 18, 2019
Sales and Marketing Cimzia, NICE, UCB Pharma, UK, pharma, plaque psoriasis, psoriasis

NICE has announced its decision to recommend UCB Pharma’s Cimzia (certolizumab pegol) for use on the NHS in England in …

News
janssen_latest_logo_on_sign_closer

Janssen’s Tremfya maintains skin clearance after 3 years in plaque psoriasis

October 22, 2018
Research and Development, Sales and Marketing Janssen, Tremfya, pharma, plaque psoriasis, psoriasis

Janssen has revealed new long-term data for its IL-23 inhibitor Tremfya (guselkumab) in moderate to severe plaque psoriasis, demonstrating skin …

News
janssen_latest_logo_on_sign

Janssen’s Tremfya shows long-term efficacy in moderate to severe plaque psoriasis

February 19, 2018
Research and Development, Sales and Marketing Janssen, Tremfyam guselkumab, pharma, plaque psoriasis, psoriasis

Janssen has unveiled new Phase 3 trial data for its IL-23 inhibitor Tremfya (guselkumab), demonstrating that the drug was able …

News
nice_new_london_office_internal_3_web

NICE recommends plaque psoriasis contender for NHS use

August 8, 2017
Manufacturing and Production, Sales and Marketing Almirall, NICE< Skilarence, drugs, life sciences, medicine, pharma, pharmaceuticals, plaque psoriasis, psoriasis

The use of Almirall’s psoriasis drug Skilarence (dimethyl fumarate) on the UK’s NHS is one step closer after NICE gave …

News
eli_lilly

FDA approves Lilly’s plaque psoriasis drug Taltz

March 23, 2016
Research and Development, Sales and Marketing Eli Lilly, Enbrel, Taltz, plaque psoriasis

The US Food and Drug Administration (FDA) has approved Eli Lilly’s Taltz (ixekizumab) for the treatment of moderate-to-severe plaque psoriasis in …

News

Latest content

BactiVac funds development of bacterial vaccines to prevent infections against antimicrobial resistance

September 28, 2023

Avalyn Pharma raises $175m in Series C financing for inhalation therapies

September 28, 2023

NMD Pharma begins phase 2 trial for spinal muscular atrophy treatment

September 27, 2023

Alfasigma to acquire Intercept Pharmaceuticals for $19 per share

September 27, 2023

Regeneron and Sanofi’s sBLA for Dupixent accepted by FDA for priority review

September 26, 2023